1. Nyame, Kwamina, Hims, Andy, Aburous, Aya, Ori, Alessandro, Abu-Remaileh, Monther. 2024. Glycerophosphodiesters inhibit lysosomal phospholipid catabolism in Batten disease. In Molecular cell, 84, 1354-1364.e9. doi:10.1016/j.molcel.2024.02.006. https://pubmed.ncbi.nlm.nih.gov/38447580/
2. Zhong, Yu, Mohan, Kabhilan, Liu, Jinpeng, Kleinman, Mark E, Wang, Qing Jun. 2020. Loss of CLN3, the gene mutated in juvenile neuronal ceroid lipofuscinosis, leads to metabolic impairment and autophagy induction in retinal pigment epithelium. In Biochimica et biophysica acta. Molecular basis of disease, 1866, 165883. doi:10.1016/j.bbadis.2020.165883. https://pubmed.ncbi.nlm.nih.gov/32592935/
3. Johnson, Tyler B, Brudvig, Jon J, Likhite, Shibi, Meyer, Kathrin, Weimer, Jill M. 2023. Early postnatal administration of an AAV9 gene therapy is safe and efficacious in CLN3 disease. In Frontiers in genetics, 14, 1118649. doi:10.3389/fgene.2023.1118649. https://pubmed.ncbi.nlm.nih.gov/37035740/
4. Augustine, Erika F, Mink, Jonathan W. . Juvenile NCL (CLN3 Disease): Emerging Disease-Modifying Therapeutic Strategies. In Pediatric endocrinology reviews : PER, 13 Suppl 1, 655-62. doi:. https://pubmed.ncbi.nlm.nih.gov/27491213/
5. Heins-Marroquin, Ursula, Singh, Randolph R, Perathoner, Simon, Schymanski, Emma L, Linster, Carole L. 2024. CLN3 deficiency leads to neurological and metabolic perturbations during early development. In Life science alliance, 7, . doi:10.26508/lsa.202302057. https://pubmed.ncbi.nlm.nih.gov/38195117/
6. Cotman, Susan L, Lefrancois, Stéphane. 2021. CLN3, at the crossroads of endocytic trafficking. In Neuroscience letters, 762, 136117. doi:10.1016/j.neulet.2021.136117. https://pubmed.ncbi.nlm.nih.gov/34274435/
智鼠故事 
